Advanced search×

TAK1 Suppresses a NEMO-Dependent but NF-@kB-Independent Pathway to Liver Cancer

Kira Bettermann, Mihael Vucur, Johannes Haybaeck, Christiane Koppe, Jörn Janssen, Felix Heymann, Achim Weber, Ralf Weiskirchen, Christian Liedtke, Nikolaus Gassler, Michael Müller, Rita de Vos, Monika Julia Wolf, Yannick Boege, Gitta Maria Seleznik, Nicolas Zeller, Daniel Erny, Thomas Fuchs, Stefan Zoller, Stefano Cairo, Marie-Annick Buendia, Marco Prinz, Shizuo Akira, Frank Tacke, Mathias Heikenwalder, Christian Trautwein, and Tom Luedde

Cancer Cell 17(5):16 (2010) PMID 20478530

The MAP3-kinase TGF-@b-activated kinase 1 (TAK1) critically modulates innate and adaptive immune responses and connects cytokine stimulation with activation of inflammatory signaling pathways. Here, we report that conditional ablation of TAK1 in liver parenchymal cells (hepatocytes and cholangiocytes) causes hepatocyte dysplasia and early-onset hepatocarcinogenesis, coinciding with biliary ductopenia and cholestasis. TAK1-mediated cancer suppression is exerted through activating NF-@kB in response to tumor necrosis factor (TNF) and through preventing Caspase-3-dependent hepatocyte and cholangiocyte apoptosis. Moreover, TAK1 suppresses a procarcinogenic and pronecrotic pathway, which depends on NF-@kB-independent functions of the I@kB-kinase (IKK)-subunit NF-@kB essential modulator (NEMO). Therefore, TAK1 serves as a gatekeeper for a protumorigenic, NF-@kB-independent function of NEMO in parenchymal liver cells.

Copyright © 2010 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.ccr.2010.03.021
Version: za2963e q8za0 q8zbe q8zcd q8zda q8zeb q8zf6 q8zg4

Similar articles you may find interesting…

  1. Assignment of the tumor protein p53 induced nuclear protein 2 (TP53INP2) gene to human chromosome band 20q11.2 by in situ hybridization.
    J J Nowak, D D Depetris, ... M-J MJ Pébusque

    Cytogenet Genome Res 108(4):362 (2005) PMID 15628030

  2. SYUNZ-16, a newly synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT k...
    Rong Deng, Jun Tang, ... Xiao-Feng Zhu

    Int J Cancer 127(1):220-229 (2010) PMID 19904742

    We found that SYUNZ-16 could inhibit AKT activity in cell-free system. Treatment of cancer cells with SYUNZ-16 decreased the phosphorylation of AKT. Additionally, SYUNZ-16 partially attenuated the phosphorylation levels of FKHR and FKHRL1 in a dose-dependent and time-dependent fashion, and led to an...